Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients

Bone Marrow Transplantation

Volumn 47, Issue 6, 2012, Pages 874-876

  Ianotto, J C ^a   Tempescul, A ^a   Yan, X ^b   Delepine, P ^c   Le Calloch, R ^a   Hardy, E ^c   Eveillard, J R ^a   Mugnier, N ^a   Berthou, C ^a   Guillerm, G ^a  

^a CHU MORVAN   (France)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; GENERIC DRUG; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; COST CONTROL; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; FEMALE; HUMAN; LETTER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION;

BIOSIMILAR PHARMACEUTICALS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES;

EID: 84862163850     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.189     Document Type: Letter

References (10)

1. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006; 21: V4-v8.
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19: 411-419.
3. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: From approval to practice. Eur J Haematol 2011; 86: 277-288.
4. Ferro HH, Juni M, Bello R, Vidal A, Diez RA, Pavlovsky S. Utilization study of filgrastim (neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients. Transfus Apher Sci 2009; 41: 87-93.
5. Ianotto JC, Tempescul A, Delepine P, Guillerm G, Hardy E, Eveillard Jr. et al. Delayed G-CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery. Am J Hematol 2011; 86: 351-352.
6. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-457.
7. Valteau-Couanet D, Faucher C, Aupérin A, Michon J, Milpied N, Boiron JM et al. Cost effectiveness of day 5 G-CSF (lenograstim) administration after PBSC transplantation: Results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005; 36: 547-552.
8. Pagliuca A, Carrington PA, Pettengell R, Tule S, Keidan J. Haemato-oncology task force of the British committee for standards in haematology. Guidelines on the use of colony-stimulating factors in haematological malignancies. Br J Haematol 2003; 123: 22-33.
9. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
10. Apperley J, Carreras E, Gluckman E, Masszi T (eds). Haematopoietic stem cell transplantation. The EBMT handbook 2008 revised version. EBMT, Paris, France, pp 171-173.